Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease.

ABSTRACT:

Purpose

Studies comparing CSF and PET tau biomarkers have included only commercial CSF assays examining specific phosphorylation sites (e.g. threonine 181, P-tau_181p) and mid-domain tau (i.e. total tau, T-tau). Moreover, these studies did not examine CSF tau levels in relation to cerebral glucose metabolism. We thus aimed to examine CSF tau measures, using both commercial and novel assays, in relation to [¹⁸F]THK5317 (tau) and [¹⁸F]FDG PET (glucose metabolism).

Methods

Fourteen Alzheimer's disease (AD) patients (seven prodromal, seven dementia) underwent [¹⁸F]THK5317 and [¹⁸F]FDG PET studies, with follow-up performed in ten subjects (six prodromal, four dementia) after 17 months. In addition to commercial assays, novel m

SUBMITTER: Leuzy A 

PROVIDER: S-EPMC6451715 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature